HealthEquity Affirms FY2027 Adj EPS Guidance of $4.66-$4.73 vs $4.72 Est; Raises FY2027 Sales Guidance from $1.410B-$1.420B to $1.411B-$1.421B vs $1.416B Est

Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings

U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma soared 157%. Okta and Veeva Systems also rose. Build-A-Bear Workshop and Healthequity fell on earnings. European and Asian markets closed mostly lower.

HealthEquity (HQY) Q2 Earnings and Revenues Top Estimates

HealthEquity reported Q3 2026 earnings of $1.24 per share, beating consensus estimates of $1.19, with revenues of $350.73 million slightly exceeding expectations. The company has outperformed the S&P 500 by 2% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating due to mixed estimate revisions, suggesting near-term performance in line with the market.

HealthEquity Reports Q2 2027 Results: Full Earnings Call Transcript

HealthEquity (NASDAQ:HQY) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga

HealthEquity shares are trading lower after the company issued Q2 financial results. The company affirmed its FY27 adjusted EPS guidance with its midpoint below estimates.